The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, finds itself at a critical juncture as it navigates a complex landscape of opportunities and challenges. The company's recent performance and ...

We recently published a list of 12 Safe Stocks to Buy for the Long Term in 2025. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other safe stocks to ...

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

After 30 years as an attorney and more than 11 on the bench, District Judge Mark Johnson retired earlier this month in what he called a fulfilling career for which ...

In his opening remarks, Idaho Senator Mike Crapo, the Finance committee's chairman, praised Kennedy's “commitment to ...

An estimated 21 million American adults suffer from clinical depression. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

Two men, Elvis Abduli, 29, and Jay Johnson, 34, were arrested during a narcotics investigation and raid in Freeport on Wednesday. Freeport Police said officers conducted a ...

ASHEVILLE, S.C. (FOX Carolina) - The Asheville Police Department reports arresting a man on drug charges after he fled from ...

Johnson & Johnson's fourth-quarter revenues and profit were driven by strong cancer drug sales. The company announced expectations for 2025 earnings to be above Wall Street estimates. However ...

According to reports, the FDA approved the Johnson & Johnson drug called Spravato (esketamine) to treat some cases of depression in the 2019 however, this was only allowed as a prescription ...